Supernus Pharmaceuticals (SUPN) has an average broker rating of 1.67, which is interpreted as a Buy, as rated by 6 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Supernus Pharmaceuticals (SUPN) : 6 Wall Street analysts covering Supernus Pharmaceuticals (SUPN) believe that the average level the stock could reach for the short term is $27.67. The maximum price target given is $37 and the minimum target for short term is around $24, hence the standard deviation is calculated at $4.84.
Shares of Supernus Pharmaceuticals, Inc. rose by 2.02% in the last five trading days and 5.81% for the last 4 weeks. Supernus Pharmaceuticals, Inc. is up 20.69% in the last 3-month period. Year-to-Date the stock performance stands at 69.27%. Supernus Pharmaceuticals (NASDAQ:SUPN): stock turned positive on Tuesday. Though the stock opened at $22.28, the bulls momentum made the stock top out at $22.84 level for the day. The stock recorded a low of $22.18 and closed the trading day at $22.75, in the green by 2.29%. The total traded volume for the day was 337,988. The stock had closed at $22.24 in the previous days trading.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder), and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR, Trokendi XR, SPN-810, SPN-812 and SPN-809.